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Abstract 
Prostacyclin is an anti-thrombotic hormone produced by the endothelium, whose 
production is dependent on cyclo-oxygenase (COX) enzymes of which two isoforms 
exist. It is widely believed that COX-2 drives prostacyclin production and that this 
explains the cardiovascular toxicity associated with COX-2 inhibition, yet the 
evidence for this relies on indirect evidence from urinary metabolites. Here we have 
used a range of experimental approaches to explore which isoform drives the 
production of prostacyclin in vitro and in vivo. Our data shows unequivocally that 
under physiological conditions it is COX-1 and not COX-2 that drives prostacyclin 
production in the cardiovascular system, and that urinary metabolites do not reflect 
prostacyclin production in the systemic circulation. With the idea that COX-2 in 
endothelium drives prostacyclin production in healthy individuals removed, we must 
seek new answers to why COX-2 inhibitors increase the risk of cardiovascular events 
in order to move forward with drug discovery and to enable more informed 
prescribing advice. 
  
Introduction 
Prostacyclin is an anti-thrombotic hormone produced by the vascular wall, inhibition 
of which has been associated with an increased risk of heart attacks and strokes (1-3). 
The production of prostacyclin is dependent upon cyclo-oxygenase (COX) enzymes, 
which convert arachidonic acid into prostaglandin H2, the precursor of all prostanoids.  
Twenty years ago it was established that COX exists in two isoforms, COX-1 and 
COX-2 (4-6). Originally it was thought that COX-2 was largely responsible for the 
pathological production of prostanoids, for instance in inflammatory conditions, but 
now it is understood that COX-2 may fulfill physiological as well as pathological 
roles (7, 8). With regard to the cardiovascular system, there has been strong debate as 
to which isoform supports the vascular production of prostacyclin and it is currently 
widely believed that COX-2 and not COX-1 is expressed within endothelial cells (1, 
2, 9, 10). Inhibition of COX isoforms explains both the therapeutic and deleterious 
effects of traditional non-steroid anti-inflammatory drugs (NSAIDs; e.g. ibuprofen, 
diclofenac) as well as COX-2-selective drugs (e.g. celecoxib, rofecoxib). As it is 
commonly believed that COX-2 in endothelial cells is responsible for prostacyclin 
release, it is also thought that inhibition of endothelial COX-2 explains the increased 
incidence of atherothrombotic events associated with the use of traditional NSAIDs 
and COX-2-selective drugs (11, 12).  
 
The idea that COX-2 drives vascular prostacyclin production is rooted 
particularly in studies showing that the urinary prostacyclin marker, 2,3-dinor-6-keto-
PGF1α (PGI-M) is reduced by COX-2 selective inhibitors (13, 14). Evidence from 
other experimental approaches, especially immunohistochemistry, has in many 
regards failed to support this conclusion (15-19); the most recent study of vascular 
targeted COX-2 gene deletion, for instance, reporting COX protein expression in cells 
in culture but not within the intact vasculature (10). Here we have used a range of 
experimental approaches including human cells, genetically modified laboratory 
animals where the COX-1 or COX-2 gene has been deleted, and measures of 
prostacyclin release in vitro and in vivo to explore which isoform drives the 
production of prostacyclin. Our data shows that under physiological conditions it is 
COX-1 and not COX-2 that drives prostacyclin production in the cardiovascular 
system, and that urinary measures of prostacyclin do not reflect endogenous 
prostacyclin levels in the systemic circulation.  The belief that COX-2 drives 
prostacyclin has had a major impact on the impetus to develop new therapeutic 
avenues and/or new drugs in the COX-2 inhibitor class. Thus, it is essential that we 
fully understand the role of COX-2 in the cardiovascular system in order to move 
forward with drug discovery and to enable more informed prescribing advice. 
 
Results and discussion 
COX expression and activity by cells in vitro and arteries ex vivo 
We have previously shown that COX-1, and not COX-2 is expressed in human aortic 
endothelial cells grown in culture under static conditions (15)
,
(20). Endothelial cells 
grown under static conditions often quickly lose phenotypic markers. In particular, it 
has been suggested that COX-2 expression is lost rapidly in endothelial cells in static 
culture but that this can be rescued by applying shear stress (21-24). This conclusion 
regarding the regulation of expression of COX-2 by shear, however, is based upon 
studies employing short periods of shear stress, which may be perceived by cells as an 
inflammatory insult that resolves with time. Previous work from our group has shown 
that chronic exposure to shear stress (up to 7 days) is not associated with increases in 
COX-2 expression in porcine aortic endothelial cells (25). Here we confirm our 
earlier observations, showing that COX-1, but not COX-2, immunoreactivity was 
abundant in human aortic endothelial cells cultured under static conditions (Figure 
1a). Furthermore, growing cells under shear stress conditions for 7 days did not 
increase COX-2 immunoreactivity. COX-2 expression (fluorescence intensity) could 
however, be increased by the addition of lipopolysaccharide (LPS) (control; 1.2±0.4: 
plus 0.1μg/ml LPS; 6.0±1.8; n=6).  This result is in accordance with previous 
observations which taken together indicate that whilst acute periods of shear stress 
induce COX-2 expression, this is a transient response of the cells and does not result 
in sustained COX-2 expression (20, 23, 24, 26, 27). Studies with isolated endothelial 
cells can only tell us so much about the situation in blood vessels where cells are 
exposed to complex patterns of shear stress for the entire life span of the animal. In 
order to address the role of COX-2 in whole blood vessels more directly, we imaged 
COX immunoreactivity in the endothelium of the mouse aortic arch. As an 
experimental model this offers both well-characterized endothelial phenotypes and a 
vessel architecture that maps to defined complex shear patterns (28-30). As we found 
in human endothelial cells, endothelium of the mouse aortic arch exhibited abundant 
COX-1 immunoreactivity with sparse levels of COX-2 (Figure 1b). In line with what 
we found for isoform expression, prostacyclin release, measured as 6-ketoPGF1α, 
from aortic arches stimulated with calcium ionophore (Figure 1c) was found to be 
COX-1 and not COX-2 dependent. Similar results were obtained in parallel studies 
using thoracic aorta stimulated with calcium ionophore (Figure 1d) or un-stimulated 
conditions (Figure 1e) and, in both cases, release could be abolished (reduced <95%) 
by the non-selective COX-1/COX-2 inhibitor, diclofenac (Supplementary Figure 1). 
Similar results were recently published by Lui and colleagues (31). These 
experiments clearly demonstrate that in the aorta COX-1 and not COX-2 mediates 
prostacyclin release. The finding that COX-1 immunoreactivity is expressed in blood 
vessels is not new, others have shown this in a variety of tissues and using a variety of 
imaging techniques (see (15-19)). It has been suggested, however, that COX-2 is a 
very unstable protein, which could be rapidly lost in post mortem processing of 
tissues explaining its absence in immunohistochemical studies (1). Indeed, here we 
report that human COX-2 protein induced by IL-1β in the human lung epithelial cell 
line, A549(32), was relatively unstable with a half-life of 2-4 hours (Supplementary 
Figure 1). In our studies, aortic arch tissue was fixed as rapidly as possible (<5 min 
post mortem) and prostacyclin release assays performed ≤10 min post mortem, well 
within the half-life for COX-2 protein (Supplementary Figure 2). In order to test 
directly the stability of COX-2 in vascular tissue we removed aorta from wild-type, 
COX-1
-/-
 and COX-2
-/-
 mice and followed the time course of COX expression and 
prostacyclin release. As before, we saw very little COX-2 expression in the 
endothelium of the aorta up until 2 hours post mortem (Figure 2a-c). Consequently, up 
to this time point, prostacyclin release was dependent upon COX-1, and not COX-2 
(Figure 2d). Paradoxically, however, we found that at time points after 2 hours, COX-
2 immunoreactivity was clearly detected in the endothelium of aorta from wild-type 
mice. In line with this, COX-2 activity took over from COX-1 as the main isoform 
driving prostacyclin release in tissue maintained in culture from 4 hours up until 7 
days (Figure 2d,e). Clearly, COX-2 is not present in healthy tissues, but can be 
rapidly induced post mortem.  
 
 
 
Microvascular COX expression and activity ex vivo 
The majority of the endothelium in the body is within organs in which different local 
stimuli will be present than in the aorta. In order to address this we investigated the 
expression of COX in lungs and hearts and found they contained abundant levels of 
COX-1 with minimal levels of COX-2 protein (Figure 3a). Importantly, as in isolated 
vessels, the release of prostacyclin by segments (Figure 3b-c) or homogenates (Table 
1) of lung or heart was completely dependent on COX-1. We also found that 
prostacyclin release from the endocardium, sampled from medium incubated within 
the chamber of the left ventricle, was dependent on COX-1 and not COX-2 (Figure 
3d). In a separate study where paired tissue samples from various organs were rapidly 
removed post mortem (<10 minutes) and incubated in parallel, we found that COX 
activity in lung, heart, kidney, liver, spleen and blood was, in each case, dependent 
upon COX-1 and not COX-2 (Figure 4).  
 
In vivo endothelial cell COX activity 
The experiments above clearly show that for all the in vitro assays of COX activity 
we conducted, COX-1 regulates prostacyclin production. In vitro studies may not 
however reflect what is happening in vivo. The notion that COX-2 regulates 
prostacyclin production in the circulation comes from measurement of the urinary 
prostacyclin marker, PGI-M, in the urine of human volunteers (13, 14) and laboratory 
animals (33). In the current study we performed similar experiments using wild-type 
and COX-2
-/-
 mice.  Mice were dosed daily with either the non-selective COX-
1/COX-2 inhibitor naproxen (30mg/kg/day), or rofecoxib (50mg/kg/day), which is a 
selective COX-2 inhibitor. Ex vivo validation studies, measuring circulating drug 
activity in the plasma of mice confirmed that naproxen inhibited both COX-1 and 
COX-2, whilst rofecoxib selectively inhibited COX-2 (Figure 5a,b). Urine was 
collected from these animals, PGI-M measured by mass spectrometry (34) and data 
analyzed as described previously (33). In line with what others have found in COX-2 
deficient mice, we found that levels of PGI-M were reduced compared to those found 
in urine of wild-type mice (Figure 5c). Moreover, in addition to naproxen, the COX-2 
inhibitor, rofecoxib, inhibited urinary PGI-M in wild-type, but not in COX-2
-/-
 mice 
(Figure 5c).  These observations are in accordance with those of others in the field 
and clearly point to urinary PGI-M being driven by a COX-2-dependent pathway, yet 
these findings are at direct odds to what we find in vessels and organs of mice ex vivo. 
We reasoned that perhaps urinary markers of prostacyclin are not reflective of levels 
in the circulation. Most recently others have found the same to be true for urinary 
markers of thromboxane (TX-M) (35). In order to consolidate our observations and 
those of others in the literature, we performed experiments in which prostacyclin 
levels in the circulation were measured as its direct breakdown product in plasma, 6-
ketoPGF1α. Circulating levels of prostacyclin are low, but can be increased by 
intravenous administration of bradykinin (36), which selectively activates endothelial 
cells but not platelets. Basal plasma levels of 6-ketoPGF1α were relatively low, but 
detectable (Figure 6). Bradykinin (100nmol/kg, i.v.) increased plasma levels of 6-
keto-PGF1α approximately 5-fold (Figure 6a). Both basal and bradykinin stimulated 6-
keto-PGF1α levels were greatly depressed in COX-1
-/-
 mice, but unaffected in COX-2
-
/- 
mice (Figure 6a), showing that endothelial derived prostacyclin in vivo, as in vitro, is 
driven by the activity of COX-1 and not COX-2. Furthermore, these results indicate 
that urinary PGI-M is not a good correlate of circulating levels of prostacyclin 
metabolite, 6-keto-PGF1α. In line with this, we found that the COX-2 inhibitor, 
paracoxib, at concentrations that spared the platelet (Figure 6b) but inhibited COX-2 
activity >85% ex vivo (Figure 6c) had no effect on basal (Figure 6d) or bradykinin-
stimulated (Figure 6e) prostacyclin release in the circulation. This data further 
corroborates the idea that prostacyclin in the circulation is driven by COX-1 and that 
urinary markers of prostacyclin are not reflective of the situation in the circulation. 
 
In healthy human endothelium and in healthy laboratory animals, therefore, COX-1, 
and not COX-2, drives prostacyclin, and urinary PGI-M levels are not reflective of the 
prostacyclin in the circulation. With the idea that COX-2 in endothelium drives 
prostacyclin production in healthy individuals removed, we must seek new answers to 
why COX-2 inhibitors increase the risk of cardiovascular events. Our group has 
previously published data showing that COX-2 inhibitors can have an acetaminophen-
like effect, inhibiting COX-1 in low lipid peroxide environments, and this may now 
warrant further research (15). Furthermore, COX-2 in the kidney has well defined 
effects on blood pressure, and so the role of COX-2 and NSAID pharmacology in 
renal function may need to be re-visited and associations between COX-2 and blood 
pressure regulation more deeply investigated (7, 10). COX-2 inhibition may also 
regulate cardiovascular health indirectly by functions in nerves or in the gut (8), or by 
affecting the progression of inflammatory disease within the circulation (9). These 
and other possibilities now need to be properly investigated in order for us to fully 
understand the effects of NSAIDs upon cardiovascular health. The prevailing dogma 
that COX-2 in the endothelium supports vascular prostacyclin production is simply 
not supported by evidence from immunohistochemical, pharmacological, or 
physiological investigations. 
 
  
Materials and Methods 
Mice 
COX1
-/-
 (37) and COX-2
-/-
 (38) mice, were back-crossed for >7 generations onto a 
C57Bl/6 background (Harlan, UK).  Wild-type mice were generated by inter-crossing 
C57Bl/6 back-crossed COX-1
+/-
 and COX-2
+/-
 mice. All mice used in the study were 
genotyped (40) to establish COX-1 and COX-2 status before use. Unless otherwise 
stated, experiments were performed on male and female 10-12 week old mice. All 
animal procedures were conducted in accordance with Animals (Scientific 
Procedures) Act 1986 and after local ethical review. 
 
Cell culture 
Human aortic endothelial cells were purchased from Lonza and cultured according to 
manufacturers instructions using recommended media (EGM-2 containing 
hydrocortisone). As hydrocortisone can inhibit the induction of COX-2, 3 days prior 
to shear experiments cells were switched to hydrocortisone-free EGM-2. Cells were 
seeded onto Transwell filters coated with fibronectin (50μg/ml; Sigma) and allowed 
to equilibrate for 24 hours before further experimentation. To assess the effect of 
shear stress, a PS-300 orbital shaker (Grant Instruments) was used as previously 
described (25). In some cultures, lipopolysaccharide (LPS; 0.1μg/ml; from 
Escherichia coli serotype 0111:B4, Sigma) was added to the media as a positive 
control. Cells were incubated under either static conditions (no shear) or shear stress 
for 7 days, with media replaced every 2 days. At the end of the experiment, media 
was removed and cells were fixed in 2% formalin (Sigma) as described previously 
(25). 
 
Immunohistochemistry and confocal imaging 
Mice euthanised with CO2 were immediately perfused across the heart with PBS 
(20ml) followed by 2% formalin (20ml) and the aortic arch was carefully removed. 
The aortic tissue was then blocked (20% normal goat serum, Vector labs) and 
permeabilized (0.1% Triton X-100, Sigma), treated with rabbit anti-mouse COX-1 
(1:50; Cayman Chemical) or rabbit anti-mouse COX-2 (1:50; Cayman Chemical) 
primary antibodies, followed by Alexa594-conjugated goat anti-rabbit IgG secondary 
antibodies (Invitrogen). Tissues were counterstained with Alexa488-conjugated rat 
anti-mouse CD31 (1:100; Biolegend) and DAPI (25ug/ml; Invitrogen). After staining, 
aortic rings were cut open to reveal the luminal surface, mounted flat between a glass 
slide and coverslip with aqueous hard-set media (Vector Labs) and pressed until the 
media had firmly set. Formalin-fixed transwell filters on which human aortic 
endothelial cells were grown were stained as aortic arches except that cells were 
blocked in 1% BSA, permeabilized in 0.2% Triton X-100, and rabbit anti-human 
COX-1 (1:250; Cayman Chemical), rabbit anti-human COX-2 (1:250; Cayman 
Chemical). Stained filters were mounted under on glass slides under coverslips with 
aquous media (Vector Labs) as we previously described (25).  
 
The luminal surface of aortic rings, and the human aortic endothelial cells-coated 
surface of the transwell filters were visualized with a Leica SP5 inverted confocal 
microscope using a 40X objective oil immersion lens. Laser and gain settings were 
fixed at the beginning of each imaging protocol. In aortic arch preparations, areas 
corresponding to the lesser and greater curvature were determined by tissue 
orientation and confirmed by the cell morphology in the CD31
+
 endothelial cell layer 
as described previously (28, 29).  For both aortic arches and human aortic endothelial 
cells coated transwell filters, non-specific binding was excluded by subtracting the 
fluorescence of tissue/cells in which the primary antibody was omitted from the 
staining protocol. The COX-1 and COX-2 immunoreactivity was quantified as mean 
fluorescence intensity using Fluorescence Lite software (Leica Microsystems) (25). 
The specificity of the antibodies used was confirmed by the ability of specific 
blocking peptides to quench immunoreactivity (Supplementary Figure 3). 
 
In vitro COX activity bioassays 
Aortic tissue, blood and various organs from animals perfused with PBS, were 
carefully dissected into small pieces (~2mm rings for aortic tissue, ~25mm
3
 for solid 
organs) and placed into individual wells of 48 or 96 well microtitre plates containing 
DMEM (200mM L-Glutamine; Sigma). For studies where tissue were incubated ex 
vivo for up to 7 days, DMEM was additionally supplemented with FCS (10%; Sigma), 
penicillin (100 U/mL; Sigma), streptomycin (100 µg/mL; Sigma), 2.5 µg/mL 
amphotericin B (2.5 µg/mL; Sigma) and non-essential amino acid solution (Sigma). 
In some studies tissues were treated with non-selective COX inhibitor diclofenac 
(100μM; Sigma) and/or the calcium ionophore, A23187 (50μM; Sigma). These 
details, as well as the period of incubation of tissues ex vivo are defined in individual 
figure legends. In some studies, after bioassay, aortic rings were fixed for 10 minutes 
in 2% formalin and COX-1 and COX-2 immunoreactivity evaluated as above. 
 
In separate studies organs were removed and homogenized in order to assay COX 
activity in cell press preparations. Prostacyclin was measured in conditioned media or 
homogenate supernatants, by selective enzyme immunoassay for 6-keto-PGF1α (a 
stable breakdown product of prostacyclin; Cayman Chemical). For blood COX 
activity, thromboxane release was measured using a selective ELISA for the 
breakdown product thromboxane B2 (Cayman chemical, USA).  
 
Western blotting 
Snap-frozen tissues were homogenised in PBS containing EDTA (10mM), Triton-X 
100 (1%), polymethylsulfonyl fluoride (1mM) and Roche protease inhibitor cocktail 
(1X) using a Precellys 24 homogeniser. Protein concentration in homogenates was 
determined by Bradford assay and samples separated by SDS-PAGE (20ug/ml total 
protein/lane). Protein was transferred onto nitrocellulose membranes, which were then 
probed with anti-COX-1 (1:1000; Cayman Chemical), anti-COX-2 (1:1000; Cayman 
Chemical), anti-beta-actin (1:10000; Dako) or anti-GAPDH primary antibodies 
(1:2000; Abcam). Immunoreactivity was visualised using corresponding HRP-
conjugated secondary antibodies (Dako) and electrochemiluminescent detection (GE 
Amersham). 
 
Urinary prostacyclin metabolite excretion 
Mice were treated for 7 days with rofecoxib (50mg/kg; Merck), naproxen (30mg/kg; 
Sigma) or vehicle (1% DMSO; VWR) by once-daily oral gavage in a randomised 
triple crossover fashion with 14 days wash out between treatments. For the final 2 
days of each treatment, mice were housed in metabolic cages for the collection of 
urine, and the urinary levels of PGI-M (2,3-dinor-6-keto-PGF1α) determined by gas 
chromatography-tandem mass spectrometry as previously described (34). To confirm 
the effectiveness and selectivity of treatments, 2 or 24 hours after the final dose of 
NSAID was administered, blood was collected for measurement of COX-1 and COX-
2 inhibitory activity as we have previously described (39). COX-1 inhibition was 
determined by stimulating whole blood with A23187 (50uM, 30 mins) and 
measurement of platelet TxB2 formation by enzyme immunoassay (Cayman 
Chemical). COX-2 inhibitory activity was determined by applying plasma to J774 
murine macrophages in which COX-2 had been induced with LPS (from Escherichia 
coli serotype 0111:B4; 10ug/ml; Sigma)-induced, before stimulation with A23187 
(50uM, 30 mins) and measurement of PGE2 formation by enzyme immunoassay 
(Cisbio).  
 
Circulating prostacyclin measurement in vivo 
Under isoflurane anesthesia, the right jugular vein and left carotid artery of wild-type, 
COX-1
-/-
 and COX-2
-/-
 mice were cannulated. Where required, the selective COX-2 
inhibitor, paracoxib (0.5mg/kg; Pfizer, UK), the non-selective COX-1/COX-2 
inhibitor diclofenac (1mg/kg; Novartis, UK) or vehicle were administered via the 
venous cannula. After a 30 min stabilisation period, 0.2ml arterial blood was 
withdrawn and 0.2ml warm saline infused into the venous canula. After a further 5 
minutes of stabilisation, bradykinin (100nmol/kg; Tocris Bioscience) was 
administered intravenously and 0.5ml arterial blood collected 5 mins later before the 
animal was euthanised. Plasma was separated from heparinized (10U/ml) blood and 
the levels of the prostacyclin breakdown product 6-keto-PGF1α measured in pre- and 
post-bradykinin plasma samples by enzyme immunoassay (Cayman Chemical). In 
parallel studies, 30 mins after treatment with paracoxib, diclofenac or vehicle, blood 
was collected for measurement of COX-1 and COX-2 inhibitory activity ex vivo as 
described above. 
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Figure 1 Expression and activity of COX-1 and COX-2 in endothelium and 
vessels. (a) Abundant COX-1 but sparse COX-2 immunoreactivity was detected in 
human aortic endothelial cells cultured under static conditions or after 7 days of shear. 
Data is representative of 6 wells using cells from 3 separate donors. (b) Abundant 
COX-1, but sparse COX-2 immunoreactivity (red) were detected in the endothelium 
of the mouse aortic arch. (a-b) Images are from aortic arches from 12 week old male 
mice and are representative of data from at least n=6 each of young (10-12 weeks) 
and aged (50-60 weeks), male and female mice. COX activity was stimulated in aortic 
arches (c) or thoracic aorta (d) by placing tissue immediately (<10 minutes after 
death) into media containing the calcium ionophore, A23187 (50μM) and incubation 
for 30 minutes or (e) placing rings of thoracic aorta into DMEM alone, and after a 1hr 
equilibration period, replacing media and incubating for 30 mins. Prostacyclin release 
was measured as the breakdown product 6-keto PGF1α by enzyme immunoassay. Data 
is the mean ± S.E.M for tissue from n=4 (d-f) mice aged 10-12 weeks. Data was 
analyzed using one-way ANOVA followed by Bonferroni’s multiple comparison test; 
*p<0.05 vs. wild-type.  
 
Figure 2 Effect of time post mortem on COX-1 and COX-2 expression and 
activity in mouse aorta. Representative images of COX-2 (a; red) and COX-1 (b; 
red) immunoreactivity in the endothelium of aorta from a wild-type mouse incubated 
ex vivo for between 0.5 and 12 hours post-mortem. Pooled mean fluorescence values 
for (b) COX-2 and (c) COX-1 immunoreactivity from n=4 separate animals, 10-12 
week old male and female wild-type mice.  (d) COX activity (as 6-keto PGF1α) 
measured in the same aortas over this time course, and (e) COX activity measured 7 
days from n=5 separate animals. 
 Figure 3 COX-1 and COX-2 protein expression and activity in mouse lung and 
heart. Western blot analysis (a) showed abundant COX-1 with little COX-2 in lungs 
or hearts wild-type mice. Mouse platelets, which contain only COX-1 and murine 
J774 macrophages treated with LPS to induce COX-2 were used as controls. COX 
activity, measured as 6-ketoPGF1α release from intact pieces of (b) lung or (c) heart  
was measured after 90 minutes equilibration followed by 30 minutes treatment with 
A23187 (50μM). COX activity within the chamber of the left ventricle (interior) was 
measured by cannulating the left ventricle of isolated hearts and after equilibration 
(90 mins) filling with A23187 (50μM) and incubating 30 minutes before collection of 
the contents. Data is the mean ± S.E.M. for n=6 male and female, 10-12 week old 
mice. Data is analyzed using one-way ANOVA followed by Bonferroni’s multiple 
comparison test; *p<0.05 vs. wild-type. 
 
Figure 4 COX activity in a range of mouse organs measured immediately after 
death. Aorta (a), heart (b), kidney (c) liver (d), blood (e) and spleen (f) were taken 
from mice and immediately placed into DMEM and stimulated with A23187 (50μM). 
After 30 minutes, conditioned media was collected and COX activity was measured 
by the formation of 6-ketoPGF1α. Data is the mean ± S.E.M. for n=4 mice. Data is 
analyzed using one-way ANOVA followed by Bonferroni’s multiple comparison test; 
*p<0.05 vs. wild-type. 
 
Figure 5 Effect of naproxen and rofecoxib in vivo on urinary prostacyclin 
metabolite (PGI-M). Mice were dosed by oral gavage daily with naproxen 
(30mg/kg), rofecoxib (50 mg/kg) or vehicle and COX inhibitory activity of their 
blood measured ex vivo (a) in A23187-stimulated whole blood for COX-1 or (b) on 
LPS-induced murine J774 macrophages for COX-2 (n=4). (c) PGI-M levels in urine 
collected from n=4 metabolic cages, each containing 3-4 mice were analyzed 
normalized to vehicle control as described previously for studies of this type (33). 
Data is the mean ± S.E.M. Data in (a) and (b) was analyzed using one-way ANOVA 
followed by Bonferroni’s multiple comparison test; *p<0.05 vs. wild-type vehicle. 
 
Figure 6 Role of COX-1 versus COX-2 in driving prostacyclin production in the 
circulation in vivo. (a) Prostacyclin release in vivo was measured as 6-ketoPGF1α 
levels in plasma under control (basal) conditions and after administration of 
bradykinin (100nmol/kg; i.v.) in wild-type, COX-1
-/-
 and COX-2
-/-
 mice (n=6). The 
COX inhibitory activity of blood from mice treated with intravenous paracoxib 
(0.5mg/kg), diclofenac (1mg/kg) or vehicle was measured ex vivo (b) in A23187-
stimulated whole blood for COX-1 or (c) on LPS-induced murine J774 macrophages 
for COX-2 (n=4). The effect of these drugs on prostacyclin release in vivo was 
measured as 6-ketoPGF1α levels in plasma under (d) control (basal) conditions and (e) 
after administration of bradykinin (100nmol/kg; i.v.) Data is mean ± S.E.M. for n=6 
male and female, 10-12 week old mice per genotype. Data was analyzed using one-
way ANOVA followed by Bonferroni’s multiple comparison test; *p<0.05 vs. wild-
type. 
  
Tables 
 
6-keto-PGF1a (ng/ml)  Wild-type COX-1
-/-
 COX-2
-/-
 
Heart  27.2 ± 8.6 4.1 ± 1.5 * 29.8 ± 10.9 
Lung  661.8 ± 59.7 7.6 ± 2.5 * 894.9 ± 72.4 
Kidney  80 ± 13.4 5.5 ± 1.7 * 77.1 ± 15.2 
Brain  31.1 ± 2.1 6.2 ± 1.1 * 23.9 ± 2.7 
 
 
Table 1 Prostacyclin associated COX activity in tissue homogenates of heart, 
lung, kidney and brain. Organs were snap-frozen immediately post-mortem, then 
homogenized in 50mM Tris buffer. Homogenates were incubated for 20 minutes at 
37°C before addition of diclofenac (1 mM) to halt residual COX activity. 
Homogenates were centrifuged and 6-ketoPGF1α measured in the supernatant by 
enzyme immunoassay. Data is mean± S.E.M. from n=4 animals. Data was analyzed 
by one-way ANOVA followed by Bonferroni’s multiple comparison test; *p<0.05 vs. 
wild-type. 
